Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick B Mark

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Lancet (London, England)|August 16, 2025
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trialMichael Walsh, David Collister, Martin Gallagher, et al.
Annals of Internal Medicine|November 3, 2025
Proteinuria or Albuminuria as Markers of Kidney and Cardiovascular Disease Risk : An Individual Patient-Level Meta-analysisHiddo J L Heerspink, Morgan E Grams, Yingying Sang, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 6, 2025
Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillationNoboru Kaneko, Godfrey L Smith, Christopher M Loughrey, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
Molecular and Cellular Endocrinology|February 11, 2018
Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantationSofia Christakoudi, Manohursingh Runglall, Paula Mobillo, et al.
Ebiomedicine|July 25, 2020
Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapySofia Christakoudi, Manohursingh Runglall, Paula Mobillo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2018
Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMANicholas M Selby, Peter J Blankestijn, Peter Boor, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Lancet (London, England)|August 16, 2025
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trialMichael Walsh, David Collister, Martin Gallagher, et al.
Annals of Internal Medicine|November 3, 2025
Proteinuria or Albuminuria as Markers of Kidney and Cardiovascular Disease Risk : An Individual Patient-Level Meta-analysisHiddo J L Heerspink, Morgan E Grams, Yingying Sang, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 6, 2025
Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillationNoboru Kaneko, Godfrey L Smith, Christopher M Loughrey, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
Molecular and Cellular Endocrinology|February 11, 2018
Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantationSofia Christakoudi, Manohursingh Runglall, Paula Mobillo, et al.
Ebiomedicine|July 25, 2020
Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapySofia Christakoudi, Manohursingh Runglall, Paula Mobillo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2018
Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMANicholas M Selby, Peter J Blankestijn, Peter Boor, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 24